What You Should Know
- Paris-based medical technology innovator BrightHeart has officially received the CE mark for its flagship medical devices, clearing the commercialization of its B-Right AI Platform across the European Union.
- The regulatory milestone arrives on the heels of the company’s recent €11 million Series A funding round and the successful launch of its platform within GE HealthCare’s Voluson™ Solution Store.
- The technology directly tackles a persistent public health crisis: up to 50% of structural congenital anomalies go entirely undetected prenatally due to severe variations in sonographer experience, localized resource constraints, and image acquisition hurdles.
- Published within Obstetrics & Gynecology, independent validation drawing from 11 academic centers proved the software identifies severe fetal structural defects with a striking 98.7% sensitivity and 97.7% specificity.
- BrightHeart will execute its broad European commercial debut at the Fetal Medicine Foundation (FMF) World Congress in Vienna, Austria, running from June 28 to July 2, 2026.
Activating Dual-Layer Clinical Intelligence at the Point of Capture
The architectural methodology driving BrightHeart’s software moves past simple post-processing filtration to act as an active, real-time AI co-pilot. Rather than forcing a sonographer to pause their examination to query an external web platform, the B-Right AI Platform operates as a non-disruptive, plug-and-play layer directly on top of major ultrasound hardware. The technology enforces standardization through two deeply integrated clinical capabilities:
Live Acquisition Guidance
The platform’s computer vision models continuously audit the live DICOM video feed during a scan, providing real-time automated view recognition. By instantly tracking the completeness of full fetal anatomy profiles and flagging potential omissions before the patient ever leaves the examination table, the system ensures strict protocol adherence regardless of operator background.
Advanced Morphological Evaluation
Once key views are documented, the software runs a detailed analysis of complex fetal structures, mirroring the diagnostic reasoning patterns of a senior pediatric cardiologist. It maps over a thousand unique anatomical landmarks per organ, explicitly highlighting abnormal findings or validating normal development with absolute structural consistency.
“Obtaining the CE mark is a critical step in BrightHeart’s mission to make high-quality prenatal screening accessible to every patient, in every center,” stated Cécile Dupont, Chief Executive Officer at BrightHeart. “Fetal ultrasound is one of the most operator-dependent examinations in medicine, leading to significant variability in quality. BrightHeart is built to close that gap, starting with cardiac screening, and extending to brain analysis and support for the full prenatal ultrasound workflow.”
Unassailable Validation: 98.7% Sensitivity Across 11 Multi-Center Cohorts
The academic and clinical validation backing BrightHeart’s entry into the European healthcare market is supported by a robust, multi-center research footprint. The platform’s performance metrics are anchored in two rigorous, peer-reviewed validation studies published within Obstetrics & Gynecology (commonly known as the Green Journal).
In a landmark standalone validation evaluating 877 complex examinations against an expert cardiologist reference standard (Zelop et al., Obstet. Gynecol., 2026), BrightHeart’s deep learning models identified findings associated with severe structural anomalies with an exceptional 98.7% sensitivity and 97.7% specificity among conclusive exams. Crucially, the platform returned clear, definitive diagnostic conclusions in 98.7% of total processed cases—proving its ability to dramatically drive down false-negative diagnostic errors and eliminate the clinical ambiguity that fuels provider uncertainty.
This exceptional precision has fueled a powerful commercial deployment pipeline. A proud portfolio company of Sofinnova Partners’ elite medical device accelerator, Sofinnova MD Start, BrightHeart recently secured a €11 million Series A funding round co-led by Odyssée Venture and GO Capital to accelerate global expansion.
Furthermore, the software has established a critical distribution channel through its availability in GE HealthCare’s Voluson™ Solution Store—the premier digital marketplace for women’s health ultrasound across the United States and Europe. By integrating its software directly within the trusted Voluson workflow ecosystem, BrightHeart allows OB/GYNs, sonographers, and Maternal-Fetal Medicine (MFM) specialists to access expert-level decision support without forcing disruptive hardware changes or adding administrative overhead.
